Get the Stockscreener App
8.87
1.14%
0.10
Pre-market:
8.94
0.07
+0.79%
Kyverna Therapeutics Inc stock is traded at $8.87, with a volume of 756.94K.
It is up +1.14% in the last 24 hours and up +4.23% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$8.77
Open:
$8.57
24h Volume:
756.94K
Relative Volume:
1.01
Market Cap:
$536.24M
Revenue:
-
Net Income/Loss:
$-161.31M
P/E Ratio:
-2.4266
EPS:
-3.6553
Net Cash Flow:
$-154.85M
1W Performance:
+10.46%
1M Performance:
+4.23%
6M Performance:
+45.89%
1Y Performance:
+312.56%
1-Day Range:
$8.5023
$9.18
1-Week Range:
$7.345
$9.30
52-Week Range:
$1.78
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
8.87 | 536.24M | 0 | -161.31M | -154.85M | -3.6553 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| May-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
Market Pulse: Can Kyverna Therapeutics Inc weather a recession2026 Historical Comparison & High Return Stock Watch Alerts - baoquankhu1.vn
[EFFECT] Kyverna Therapeutics, Inc. SEC Filing - stocktitan.net
Kyverna Therapeutics enters open market sale agreement with Jefferies dated March 27, 2025SEC filing - marketscreener.com
Kyverna Therapeutics (NASDAQ: KYTX) registers $100M ATM via Jefferies - stocktitan.net
HC Wainwright Analysts Increase Earnings Estimates for KYTX - MarketBeat
[144] Kyverna Therapeutics, Inc. SEC Filing - stocktitan.net
Late-stage trial testing KYV-101 seeking adults with hard-to-treat gMG - Myasthenia Gravis News
Brokers Issue Forecasts for KYTX FY2027 Earnings - MarketBeat
Goodwin Advises Kyverna Therapeutics On $100 Million Proposed Public Offering Of Common Stock - mondaq.com
KYTX SEC FilingsKyverna Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Kyverna Therapeutics files $300M mixed securities shelf - MSN
AI Stocks: Can Kyverna Therapeutics Inc weather a recessionPortfolio Return Report & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Hyperion DeFi (HYPD), Kyverna Therapeutics, Inc. (KYTX) and Medios AG (OtherMEDOF) - The Globe and Mail
KYTX Stock Price, Quote & Chart | KYVERNA THERAPEUTICS INC (NASDAQ:KYTX) - ChartMill
Kyverna Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
KYTX: Miv-cel demonstrates transformative efficacy in autoimmune diseases, targeting SPS and gMG first - TradingView
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Kyverna Therapeutics (NASDAQ:KYTX) Announces Earnings Results - MarketBeat
Kyverna Therapeutics (NASDAQ: KYTX) files $300M shelf; $100M ATM via Jefferies - Stock Titan
Kyverna Therapeutics 10-K: $161.3M net loss, operating expenses $169.8M; cash runway ≥1 year - TradingView
Kyverna Therapeutics (KYTX) advances SPS, gMG CAR T programs and next-gen cell therapy platform - Stock Titan
[8-K] Kyverna Therapeutics, Inc. Reports Material Event - Stock Titan
Kyverna Therapeutics (KYTX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Kyverna Therapeutics Defeats Claims It Omitted Data From Its IPO - Bloomberg Law News
Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Investment Report: How much upside does Kyverna Therapeutics Inc have2026 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Levels Update: What is Kyverna Therapeutics Incs book value per share2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Kyverna Therapeutics (KYTX) CFO receives new stock options and RSU grant - Stock Titan
Kyverna (KYTX) CEO receives 350,000 options and 58,000 RSUs in equity grants - Stock Titan
Kyverna Therapeutics (KYTX) awards stock options and RSUs to officer Naji Gehchan - Stock Titan
What is Kyverna Therapeutics Incs book value per share2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
HC Wainwright & Co. Maintains Kyverna Therapeutics (KYTX) Buy Recommendation - MSN
KYTX stock just surged 11% today – what is the connection with stiff person syndrome? - MSN
William Blair Initiates Coverage of Kyverna Therapeutics (KYTX) with Outperform Recommendation - MSN
Kyverna Therapeutics (KYTX) Price Target Increased by 16.46% to 23.46 - MSN
KYTX: Pivotal miv-cel data in SPS shows disease reversal, with BLA filing and launch planned this year - TradingView
How Kyverna Therapeutics Inc. stock compares to growth peersWeekly Stock Report & Long Hold Capital Preservation Tips - Naître et grandir
Portfolio Recap: Is Kyverna Therapeutics Inc stock trending bullishBreakout Watch & Safe Entry Zone Tips - baoquankhu1.vn
Kyverna to present stiff person syndrome trial data at AAN meeting - Investing.com Australia
Kyverna secures up to $150M loan facility from Oxford Finance - MSN
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - The Manila Times
Kyverna Therapeutics Announces Presentations on Miv-cel Research at AAN Annual Meeting 2026 - Quiver Quantitative
New cell therapy data in stiff person syndrome set for AAN 2026 - Stock Titan
Aug Fed Impact: What is the Moat Score of Kyverna Therapeutics IncWeekly Profit Recap & Verified Short-Term Trading Plans - baoquankhu1.vn
Director Andrew Craig Miller files initial Form 3 at Kyverna (KYTX) - Stock Titan
Kyverna Therapeutics (KYTX) director awarded options and RSUs in equity grant - Stock Titan
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - Bitget
Biotech Kyverna lines up March talks at Leerink, Jefferies events - stocktitan.net
Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution - Seeking Alpha
P5002025 Year in Review & Long-Term Safe Return Strategies - mfd.ru
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):